caprotec bioanalytics closes Series B financing for EUR 5 million

caprotec bioanalytics GmbH, a privately held biopharmaceutical company offering the proprietary Capture Compound Mass Spectrometry (CCMS) platform technology for the analysis of small molecule – protein interactions, today announced a second closing of EUR 1 million ($1.4 M) to its Series B financing, increasing total equity for the round to EUR 5 million ($7.2 M). The capital increase was fully subscribed by LBBW Venture Capital GmbH, Stuttgart, joining existing investors Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds, and well-known private investors.

Prof. Dr. Hubert Koster, CEO of caprotec bioanalytics GmbH, commented, "This additional funding from LBBW Venture will allow us to further leverage caprotec's CCMS technology into additional markets as diagnostics and will put the company in a position to execute several large pharma partnerships at the same time."

Dr. Harald Poth, Senior Investment Manager of LBBW Venture, added, "caprotec's CCMS technology has the potential to solve the most expensive problem in the pharmaceutical industry, the failure of drug candidates in clinical trials due to off-target interactions. With caprotec's functional proteomics platform it is possible to profile small molecule drug – protein interactions, including membrane proteins in the human proteome to reveal possible off-target proteins causing adverse side effects, early in the drug development process and to use that information to structurally optimize the drug candidates."

Source:

caprotec bioanalytics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Study demonstrates how pan-sarbecovirus ORF7a protein plays a role in evading host immunity